TBXT: A Potential Cancer Drug Target Or Biomarker (G6862)

Target Name: TBXT

NCBI ID: G6862

TBXT

TBXT: A Potential Cancer Drug Target Or Biomarker

TBXT (Protein T) is a protein that is expressed in human tissues and has been shown to play a role in the development and progression of various diseases, including cancer. As a result, TBXT has generated a lot of interest as a potential drug target or biomarker.

The protein TBXT is derived from the tumor suppressor protein p53. It consists of 150 amino acid residues and has a calculated molecular weight of 17.9 kDa. The protein has a characteristic linear or fusiform structure and is expressed in various tissues, including muscle, heart, liver, and kidney.

One of the key features of TBXT is its ability to interact with and inhibit the activity of the oncogene p53. p53 is a tumor suppressor protein that plays a crucial role in maintaining the stability of genomic DNA and preventing the formation of cancer cells. However, in many cases, p53 can become hyperactive and contribute to the development and progression of cancer.

TBXT has been shown to inhibit the activity of p53 in various cell lines and animal models of cancer. This suggests that it may be an effective drug or biomarker for cancer treatment. In addition, the ability of TBXT to enhance the sensitivity of cancer cells to chemotherapy suggests that it may also be a useful tool for cancer diagnosis and prognosis.

Another potential application of TBXT is its role in aging and age-related diseases. As we age, the levels of TBXT in various tissues decline, which can lead to an increased risk of age-related diseases such as heart disease, diabetes, and cancer. Therefore, increasing the expression of TBXT may be a potential way to prevent or treat age-related diseases.

In addition to its potential therapeutic applications, TBXT has also generated a lot of interest as a potential biomarker for cancer. The ability of TBXT to be expressed and processed in cancer cells makes it an attractive candidate for use as a diagnostic or prognostic marker in cancer patients.

TBXT has been shown to be expressed in various types of cancer, including breast, lung, and colorectal cancer. In addition, the levels of TBXT have been shown to be correlated with the severity of cancer and the response to chemotherapy. This suggests that TBXT may be an effective tool for cancer diagnosis and treatment, particularly in cases where the disease is advanced or has not responded to traditional therapies.

In conclusion, TBXT is a protein that has generated a lot of interest as a potential drug target or biomarker for cancer. Its ability to interact with and inhibit the activity of the oncogene p53 makes it an attractive candidate for cancer treatment, as well as a potential tool for cancer diagnosis and prognosis. Further research is needed to fully understand the role of TBXT in cancer and its potential as a drug or biomarker.

Protein Name: T-box Transcription Factor T

Functions: Involved in the transcriptional regulation of genes required for mesoderm formation and differentiation. Binds to a palindromic T site 5'-TTCACACCTAGGTGTGAA-3' DNA sequence and activates gene transcription when bound to such a site

The "TBXT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TBXT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets